News | February 23, 2022
Agilent posts Q1 FY2022 revenue at US$ 1.67 billion
Revenue of $1.67 billion represents 8% reported growth; and up 9% on a core(basis.
Revenue of $1.67 billion represents 8% reported growth; and up 9% on a core(basis.
Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
The SureSTART consumables portfolio is designed for higher performance requirements, while meeting customer budgets
US $ 555,000 invested by Wavemaker Partners in pre-seed round
Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
In the interim, Deepak Khanna will lead Human Health International.
Since the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra
The partnership is already underway having launched earlier last week, and the contract could be worth up to £211 million.
Darolutamide is developed jointly by Bayer and Orion Corporation
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
Subscribe To Our Newsletter & Stay Updated
